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Abstract
Background: Although life expectancy estimation is vital to decision making for localized prostate cancer, there are
few, if any, valid and usable tools. Our goal was to create and validate a prediction model for other cause mortality
in localized prostate cancer patients that could aid clinician’s initial treatment decisions at the point of care.
Methods: We combined an adjusted Social Security Administration table with a subset of comorbidities from a
UK actuarial life expectancy model. Life tables were adjusted on the basis of survival data from a cohort of almost
10,000 radical prostatectomy patients treated at four major US academic institutions. Comorbidity-specific odds
ratios were calculated and incorporated with baseline risk of mortality. We externally validated the model on 2898
patients from the Prostate Cancer Outcomes Study, which included men diagnosed with prostate cancer in six
SEER cancer registries. These men had sufficient follow-up for our endpoints of 10- and 15-year mortality and also
had self-reported comorbidity data.
Results: Life expectancy for prostate cancer patients were close to that of a typical US man who was 3 years
younger. On external validation, 10- and 15-year concordance indexes were 0.724 and 0.726, respectively. Our
model exhibited excellent calibration. Taking into account differences between how comorbidities are used in the
model versus how they were recorded in the validation cohort, calibration would improve for most patients, but
there would be overestimation of the risk of death in the oldest and sickest patients.
Conclusions: We successfully created and externally validated a new life expectancy prediction model that, while
imperfect, has clear advantages to any alternative. We urge consideration of its use in counseling patients with
localized prostate cancer.
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Background
Life expectancy plays an important role when determining
appropriate treatment options for prostate cancer patients.
The slow growing nature of the disease complicates treat-
ment decisions because some patients, such as those who
are older or who have significant comorbidity, should not
be candidates for invasive procedures such as radical pros-
tatectomy. The National Comprehensive Cancer Network
(NCCN) recommends active surveillance or observation
as an alternative treatment option for managing prostate
cancer in patients who meet specific guidelines based on
tumor characteristics and life expectancy. However, the
guidelines make questionable recommendations on how
clinicians should estimate life expectancy for prostate can-
cer patients [1]. The current advice is to adjust the Social
Security Administration tables [2] by adding 50 % for pa-
tients in the top quartile and subtracting 50 % for patients
in the lowest quartile of health. This is a problematic ap-
proach for two reasons. First, the determination of a pa-
tient’s health quartile is left up to the subjective judgment
of the clinician, an approach that is not validated. Second,
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the method results in some unusual recommendations,
such as surgery being an option for 25 % of 80-year-olds
with low risk cancer: life expectancy for an 80-year-old is
8 years; add 50 % for patients in the top quartile of health
gives 12 years; and surgery is included as a possibility for
patients with a life expectancy of 10 years or more.
The American Urological Association (AUA) guide-
lines similarly recommend different treatment options
based on patient life expectancy: “Life expectancy, rather
than patient age, is a major factor to consider in treat-
ment selection” [3]. Although the AUA mentions life ex-
pectancy throughout their guidelines, and states that
patients with shorter life expectancies may opt for active
surveillance, the only reference for estimating life ex-
pectancy is the 2003 United States life tables [4].
As life expectancy estimation is integrated directly with
the clinical recommendations of major guidelines, one
might expect a plethora of tools to be available in the lit-
erature for clinician use. We previously reported a system-
atic review in which we found a dearth of accurate life
expectancy tools that could be incorporated into clinical
workflow [5, 6]. Tools gave estimates of life expectancy
that could not be integrated with cancer risk estimates,
used invalid or unsubstantiated methods to adjust life ex-
pectancy for comorbidity, and provided estimates that ap-
pear implausible or could not be easily used in routine
clinical practice. For example, the most widely used co-
morbidity index, Charlson [7], gives HIV a risk score 6
times greater than that of myocardial infarction. In a con-
temporary cohort of patients presenting with prostate can-
cer, it is unclear if these are reasonable risk estimates. As
another example, Kim et al. published an online tool to
estimate prostate cancer mortality [8]. For a typical con-
temporary patient with screen-detected cancer, the model
uses only age and Gleason score and cannot incorporate
health status. Moreover, risks seem on the high side: a 65-
year-old male of average health and Gleason 6 disease is
given an 11 % risk of prostate cancer mortality, despite
there being many investigators who question whether
Gleason 6 even counts as cancer [9]. Given the importance
of using life expectancy to determine treatment options
for prostate cancer patients, and the lack of validated life
expectancy estimation tools available to assist clinicians,
we aimed to build a prediction model for the risk of death
from other causes based on patient age and comorbidities.
Specifically, the model would provide risk estimates and
not remaining number of life years, use a valid approach
to defining comorbidities, be in a form that could be read-
ily implemented in the clinical setting, provide plausible
risk estimates, and could be individualized to each patient.
Methods
The typical approach for building a prediction model—ob-
taining a data set with outcomes and predictors and then
fitting coefficients—is not optimal for estimating
comorbidity-adjusted risk of non-cancer mortality in
patients presenting with prostate cancer. This is pri-
marily because even the largest prostate cancer data
sets are too small to provide accurate estimation for the
effects of each of a wide range of comorbidities. There-
fore, we chose to take an alternative approach, creating
the model by combining information from a variety of
different sources.
We started with the measure of actuarial life expect-
ancy (MALE) model to estimate comorbidity risk [10].
This model was selected on the grounds that it had been
developed using a very large life insurance database and
was the only model we found to provide the risk of
death from specific comorbidities. However, we found
the MALE model far too complex to be used in routine
clinical practice due to the level of detail required for each
comorbidity, such as the classification of angina or the
sub-type of atrial fibrillation. Our approach therefore was
to use a reduced subset of MALE comorbidities, chosen in
consultation with urologists at Memorial Sloan Kettering
Cancer Center (MSKCC). The comorbidities included
hypertension (defined as systolic ≥160 mm Hg and dia-
stolic ≥90 mm Hg), angina, congestive heart failure, heart
attack, aortic stenosis, atrial fibrillation, asthma, abdominal
aortic aneurysm, peripheral vascular disease, deep venous
thrombosis, pulmonary embolus, stroke, smoking, and dia-
betes. In some cases, the MALE questions were simplified
down, for instance, the original MALE question on pul-
monary embolus gave different risks for recurrent vs. sin-
gle episode; this was modified to ask only about any
history of pulmonary embolus. We also included choles-
terol in the model because some comorbidities had differ-
ent risk estimates for different cholesterol levels. These
levels include high total cholesterol (>270 mg/dL) and low
high-density lipoprotein (HDL) (<20 mg/dL).
The MALE model only provided risks of death for
each comorbidity at 10 and 15 years. To convert these
risks into odds ratios, we took the ratio of risk of death
with no comorbidities to the risk of death with the co-
morbidity of interest. This allowed us to calculate odds
ratios at both 10 and 15 years. If a patient presented
with multiple comorbidities, their odds ratios were
multiplied together.
Next, we estimated baseline risk of death on the basis of
age. We found the MALE model to be poorly calibrated
for the US population. For instance, the model gives an es-
timated 15-year survival probability of 55 % for a healthy
65-year-old. The estimate for all 65-year-old Americans
from the Social Security Administration life tables [2] is
higher, at 59 %, even though this estimate includes men
who are seriously ill. We therefore chose to recalibrate the
MALE model on the basis of US data, but with an adjust-
ment factor to reflect the population that presents for
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treatment of localized prostate cancer is healthier than
average. To derive this adjustment, we analyzed survival
data from close to 10,000 radical prostatectomy patients
treated at four major US academic institutions [11], data
for which has been published. We explored the difference
between survival curves in our data set and those of the
Social Security Administration tables. Once a patient’s
age-specific baseline risk of death was obtained it could be
adjusted accordingly based on their comorbidities to ob-
tain a final estimate of comorbidity-adjusted risk of death.
We then externally validated our final model on a co-
hort of 2,898 patients from the Prostate Cancer Out-
comes Study (PCOS) [12]. This cohort consisted of men
diagnosed with biopsy-proven prostate cancer between
October 1, 1994 and October 31, 1995 in six of the SEER
cancer registries in the states of Connecticut, Utah, and
New Mexico and the Metropolitan areas of Atlanta
(GA), Los Angeles (CA), and Seattle (WA). These men
had sufficient follow-up for our endpoints of interest
and also had information on a subset of the comorbidi-
ties used in our model, including angina, congestive
heart failure, diabetes, heart attack, stroke, and high
blood pressure. These comorbidities were captured using
a self-reported health-related quality of life (HRQOL)
questionnaire at 6, 12, and 24 months, which allowed
patients to indicate if they were ever diagnosed with a
specific comorbidity. However, this cohort did lack some
of the comorbidities used in our model, specifically aor-
tic stenosis, atrial fibrillation, asthma, abdominal aortic
aneurysm, peripheral vascular disease, deep venous
thrombosis, pulmonary embolus, smoking, and choles-
terol levels. Furthermore, hypertension was defined
more liberally in PCOS than is used in our model.
Hence we planned to interpret our results in the context
of differences in comorbidity documentation. Discrimin-
ation, as measured by the Harrell’s concordance index,
and calibration were used to assess model fit at both 10
and 15 years. Our model was “locked down” before be-
ing applied to the validation cohort, and no changes
were made subsequently. All statistical analyses were
performed using Stata 12.0 (StataCorp, College Station,
TX, USA).
Results
When estimating baseline risk of death, we found close to
a 3-year difference in survival between radical prostatec-
tomy patients and the general population represented by
the Social Security Administration tables. In other words,
the survival curves for death from other causes seen
amongst 60-year-olds presenting for prostate cancer treat-
ment approximately mirrored those seen in 57-year-olds
in the Social Security Administration data. Therefore, we
shifted the age-associated risks from the Social Security
Administration table down by 3 years to obtain the risks
used in our model. Table 1 presents a subset of these risks
at both 10 and 15 years.
The 10- and 15-year odds ratios for the subset of co-
morbidities from the MALE model are presented in
Table 2. Our subset consisted of 14 different comorbidi-
ties with varying levels of risk within comorbidities and
also interactions between comorbidities. For example,
diabetes has multiple odds ratios depending on how long
a patient has been a diabetic. Similarly, some comorbidi-
ties are influenced by cholesterol, with different odds ra-
tios for different cholesterol levels. These interactions
and variations in risk were derived directly from the
MALE model.
Table 3 presents the patient characteristics of the
PCOS cohort used for model validation. As shown, the
cohort included data on only a subset of the necessary
Table 1 Risk of overall death at 10 and 15 years by age
Age (years) 10 years 15 years
SSA risk SSA-adjusted risk SSA risk SSA-adjusted risk
50 8 % 6 % 14 % 11 %
51 8 % 7 % 15 % 12 %
52 9 % 7 % 16 % 13 %
53 10 % 8 % 17 % 14 %
54 10 % 8 % 19 % 15 %
55 11 % 9 % 20 % 16 %
56 12 % 10 % 21 % 17 %
57 13 % 10 % 23 % 19 %
58 14 % 11 % 25 % 20 %
59 15 % 12 % 26 % 21 %
60 16 % 13 % 28 % 23 %
61 17 % 14 % 31 % 25 %
62 18 % 15 % 33 % 26 %
63 20 % 16 % 35 % 28 %
64 22 % 17 % 38 % 31 %
65 23 % 18 % 41 % 33 %
66 25 % 20 % 44 % 35 %
67 27 % 22 % 47 % 38 %
68 30 % 23 % 51 % 41 %
69 32 % 25 % 54 % 44 %
70 35 % 27 % 58 % 47 %
71 37 % 30 % 61 % 51 %
72 40 % 32 % 65 % 54 %
73 43 % 35 % 69 % 58 %
74 47 % 37 % 73 % 61 %
75 50 % 40 % 77 % 65 %
SSA risk comes from the Social Security Administration risk tables, while the
adjusted risk takes into account a 3-year age shift due to patients presenting
with localized prostate cancer being healthier on average. The latter estimates
are used in our model
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comorbidities included in our model. In total, 1,041 pa-
tients died from other causes and 307 died from prostate
cancer with a median follow-up time for survivors of
13 years. Figure 1 shows the probability of prostate can-
cer survival; 10- and 15-year survival was 91 % and
85 %, respectively.
When we applied our model to the PCOS cohort we
found the discrimination (c-index) to be 0.724 and 0.726
at 10 and 15 years, respectively. Figures 2 and 3 present
the 10- and 15-year calibration plots. We can see that our
model exhibited generally good calibration for 10-year risk
of death, but overestimated risk of death for patients at
very high risk (>50 % risk of death at 10 years). For
15-year risk of death, we found much less miscalibration.
Additionally, it can be seen from the calibration plots, the
models separate risk very well. For example, in both the
10- and 15-year plots, 10 % of patients have risks of death
less than 15 % and 10 % have risks greater than 90 %.
Discussion
We previously found deficiencies in current tools that pre-
dict life expectancy or risk of death from other causes.
Tools were either difficult to use in the clinical setting or
provided questionable estimates or recommendations,
such as surgery for low risk cancer in a healthy 80-year-
old [5]. We created a new model by making common
sense adjustments to two existing tools. We reduced risks
obtained from US life tables on the grounds that these in-
clude patients too ill to present for treatment of localized
prostate cancer, and adapted a UK-based comorbidity as-
sessment model to make it feasible to use clinically. We
Table 2 Comorbidity odds ratios for 10- and 15-year risk of
death
Comorbidity 10 years 15 years
Hypertension 1.29 1.38
Angina 1.55 1.62
+ High total cholesterol 1.84 2.08
+ Low HDL 2.26 2.72
+ High total and low HDL 3.12 4.09
Congestive heart failure 3.82 3.67
Heart attack 1.55 1.62
+ High total cholesterol 1.84 2.08
+ Extremely low HDL 2.26 2.72
+ High total cholesterol and low HDL 3.12 4.09
Aortic stenosis 1.29 1.38
+ High total cholesterol 1.62 1.76
+ Extremely low HDL 2.00 2.27
+ High total cholesterol and low HDL 2.77 3.67
Atrial fibrillation 1.29 1.38
Asthma (mild) 1.17 1.17
Asthma (moderate) 2.00 2.27
Asthma (severe) 2.45 2.85
Abdominal aortic aneurysm 1.92 1.99
Peripheral vascular disease 1.62 1.76
+ High total cholesterol 2.00 2.27
+ Extremely low HDL 2.36 2.85
+ High total and extremely low HDL 3.25 4.60
Deep venous thrombosis 1.84 1.99
+ High total cholesterol 2.17 2.60
+ Extremely low HDL 2.56 3.30
+ High total and extremely low HDL 3.52 4.89
Pulmonary embolus 1.00 1.00
+ High total cholesterol 1.29 1.38
+ Extremely low HDL 1.62 1.76
+ High total and extremely low HDL 2.36 2.85
Current smoker 2.00 2.00
Former smoker 1.50 1.50
Diabetes
0–5 years 1.00 1.00
6–10 years 1.62 1.76
11–20 years 2.00 2.27
>20 years 2.36 2.85
Stroke
Hemorrhage 1.62 1.76
Infarction, thrombosis, embolism 2.36 2.85
For example, a 65-year-old man would have a risk of death from other causes at
10 years of 18 % (Table 1), an odds of 18:82. If he smoked (odds ratio of 2.0), this
would shift the odds to 36:82, a risk of 36 ÷ (36 + 82) = 31 % risk. Similar calculations
could be made to calculate the man’s risk if he had angina (odds ratio of 1.55, risk
25 %) or both angina and smoking (odds ratio of 1.55 × 2.0, risk of 40 %)
Table 3 PCOS validation set patient characteristics. All values
are median (IQR) or frequency (%)
Characteristic N = 2,898
Patient age 67 (60, 73)
Patient race
White 2,032 (70 %)
Black 475 (16 %)
Hispanic 391 (13 %)
Patient treatment type
Surgery 1,448 (50 %)
Radiation 688 (24 %)
Watchful waiting 483 (17 %)
Isolated androgen deprivation therapy (ADT) 279 (10 %)
Angina 387 (13 %)
Congestive heart failure 210 (7.2 %)
Diabetes 512 (18 %)
Heart attack 305 (11 %)
High blood pressure 1,234 (43 %)
Stroke 146 (5.0 %)
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applied this new model to an independent cohort and
found that our model exhibited good discrimination and
calibration.
Our model is not without limitations. It is not ideal to
have to merge an adaptation of a UK-based comorbidity
assessment with modified US life expectancy data. But
we had little choice: data sets with long-term follow-up
of localized prostate cancer have not had rich informa-
tion on comorbidities nor been large enough to estimate
the prognostic impact of these comorbidities.
Additionally, the PCOS study did not capture all the
comorbidities used in our model. Therefore, since some
comorbidities were unreported, the patient’s risk of
death would have been underestimated in the current
study, compared to using the model in practice when
the full spectrum of comorbidities would be obtained.
However, comorbidities reported in PCOS are likely cor-
related with the unreported comorbidities; for instance,
atrial fibrillation (unreported) with history of heart at-
tack (reported)—this would shift the highest risk patients
to the right on the calibration curve. On the other hand,
PCOS used a lower cut-point for hypertension than in
our model, with the result that more PCOS patients
than expected had hypertension. Correcting for this ef-
fect would shift the calibration curve to the left, leading
to an improved estimate of performance overall. Hence
the anticipated effect of inconsistency between the
PCOS comorbidities and those used in our model would
be improved calibration for most patients, but overesti-
mated risk for the oldest and sickest patients. We believe
Fig. 1 Cumulative hazard curves for the PCOS cohort. Solid line, prostate cancer; dashed line, other cause mortality
Fig. 2 10-year calibration plot
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that such overestimation is clinically irrelevant, because
whether a patient has, say, a 90 % or 95 % risk of death
from other causes at 15 years would make little or no
difference to clinical decision making.
Our tool can be combined with existing untreated
prostate cancer mortality estimates to obtain an adjusted
risk of prostate cancer mortality, taking into account age
and comorbidities. Rider et al. [13] present risks of un-
treated prostate cancer mortality classified into risk and
age categories. These estimates were from 117,328
Swedish men who were not treated with curative intent.
However, since the cohort consisted of patients from
1991 to 2009, we had to take into account the shift in
Gleason grading that took place in the early 2000s [14].
We assumed that 25 % of patients previously scored as
Gleason 6 in 1990–2005 would be Gleason 7 on contem-
porary grading. Upgraded patients were assigned a risk
equal to the average of the low and intermediate groups.
These estimates are based on a study in which tumors
graded in 1990–1992 were regraded in 2002–2004: the
net upgrading from Gleason 6 was 19 %, with about one-
third of upgrades to Gleason 8 or higher; this is approxi-
mately equivalent in risk terms to 25 % being upgraded to
Gleason 7 [15]. The adjusted risks are presented in
Additional file 1: Table S1. To determine a patient’s risk,
Rider et al. grouped patients by clinical stage, Gleason
score, and prostate-specific antigen (PSA). Although PSA
is an extremely strong predictor of mortality in the popu-
lation of men without a cancer diagnosis [16–18], it is not
a strong predictor of mortality in men who have been di-
agnosed with localized prostate cancer, once stage and
grade are known [19]. Accordingly, we exclude PSA as a
risk criterion, that is, assignment to high, low, or inter-
mediate risk is based purely on stage and grade.
Given the risks from our life expectancy model and
the adjusted estimates for untreated prostate cancer
mortality, we are able to calculate using conditional
probability a key estimate of clinical value: the probabil-
ity that the patient would die of prostate cancer were he
to be managed conservatively, taking into account the
probability that he would not die of another cause.
Additional file 1: Table S2 shows example data and out-
puts for a selection of patients. Note that this includes
patients with a risk of other cause mortality greater than
50 % at 10 years, that is, patients with a life expectancy
less than 10 years: there is no reason why the model
cannot be used with such patients.
These models are currently available on https://
www.mskcc.org/nomograms/prostate under male life ex-
pectancy. Additional file 1: Figure S1 shows a report of
the results that displays the text describing both the pa-
tient’s comorbidities and cancer characteristics; the risk
of death from untreated prostate cancer; comorbidity-
adjusted risk of death; and risk of death from prostate
cancer, taking into account comorbidities. We intend to
refine further the model for prostate cancer death to
take into account differences in risk within Gleason cat-
egories (e.g. 3 + 4 vs. 4 + 3) as well as the different im-
pact of stage compared to grade.
We are aware that our model is limited by the prede-
fined set of comorbidities. Naturally, it would not be
feasible to include all of the many thousands of diseases,
and their subcategorizations, in a tool to be used in
clinic. There would also be considerable computational
challenges in modeling how the prognostic effect of
many diseases changes over time, as new treatments are
developed. Hence, as would be true for any model, clin-
ical judgment needs to be exercised when using the
Fig. 3 15-year calibration plot
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estimates from our model to aid treatment decision
making. Such clinical judgment would need to incorpor-
ate considerations of disease severity (for instance, early
stage congestive heart failure compared to disabling dis-
ease); diet, exercise and other lifestyle factors; and co-
morbidities not included in the tool (consider a patient
recently diagnosed with advanced colorectal cancer).
Conclusions
Estimating the risk of other cause mortality is a key as-
pect of treatment decision making in early stage prostate
cancer. We have previously demonstrated the need for
improved tools to make this assessment. As such, we
urge consideration of our model for counseling prostate
cancer patients about treatment options.
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